Innate Pharma’s (IPHA) “Buy” Rating Reaffirmed at HC Wainwright

Innate Pharma (NASDAQ:IPHA)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They presently have a $11.50 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 408.85% from the company’s previous close.

Innate Pharma Trading Down 0.9 %

Shares of NASDAQ:IPHA opened at $2.26 on Friday. The stock has a 50-day simple moving average of $2.21 and a 200-day simple moving average of $2.40. Innate Pharma has a 1 year low of $1.81 and a 1 year high of $3.15. The company has a current ratio of 3.73, a quick ratio of 3.73 and a debt-to-equity ratio of 0.60.

Innate Pharma Company Profile

Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.